By Fineline Cube 
Japan-based Takeda Pharmaceutical (TYO: 4502, NYSE: TAK) reported financial results for the first quarter of fiscal year 2025 (FY2025Q1, April 1, 2025~June 30, 2025). Revenue for the quarter decreased 3.7% year-over-year (YOY) at constant exchange rates (CER) to JPY 1,106.7 billion (USD 7.46 billion). Core operating profit was JPY 321.8 billion (USD 2.17 billion), representing an 11.9% YOY drop.
Decline Factors
The revenue and core operating profit decline compared to the same period last fiscal year was primarily due to unfavorable foreign exchange rates and generic competition. Takeda noted that despite these impacts, the overall performance remained in line with the company’s expectations for the quarter. The company anticipates that these impacts will gradually diminish in the coming quarters, and its full-year outlook released in May remains unchanged.
Product Sales Performance
- GI (Gastrointestinal and Inflammation): Revenue was JPY 339.3 billion (+2.6%), driven by Entyvio (vedolizumab) for ulcerative colitis (UC) and Crohn’s disease (CD), with sales at JPY 232.5 billion (+4.9%).
- Rare Diseases: Revenue was JPY 196.4 billion (+3.0%), led by Takhzyro (lanadelumab) with sales of JPY 55.1 billion (+3.7%).
- PDT (Plasma-Derived Therapies): Revenue was JPY 260.9 billion (+1.7%), with immunoglobulin products contributing JPY 194.0 billion (+2.0%).
- Oncology: Revenue was JPY 138.8 billion (+1.8%), with Adcetris (Brentuximab Vedotin) for malignant lymphomas up 13.2%.
- Vaccines: Revenue declined 6.2% to JPY 11.5 billion, primarily due to a decrease in Qdenga sales.
- Neuroscience: Revenue dropped 32.6% YOY, largely due to the continued impact of generic competition on Vyvanse/Elvanse (-46.9%) for attention deficit hyperactivity disorder (ADHD).
R&D Milestones
Takeda achieved several key milestones across its global R&D pipeline, reinforcing its long-term growth trajectory. Notably, two pivotal Phase 3 studies of oveporexton (TAK-861) for Narcolepsy Type 1 (NT1) delivered positive results, meeting all primary and secondary endpoints.-Fineline Info & Tech